AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phosphoribosyl pyrophosphate synthase-associated protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O60256

UPID:

KPRB_HUMAN

Alternative names:

41 kDa phosphoribosypyrophosphate synthetase-associated protein

Alternative UPACC:

O60256; B4E1M8; B4E329; B7ZKZ1; E7EMY2; Q6IAS2

Background:

Phosphoribosyl pyrophosphate synthase-associated protein 2, also known as the 41 kDa phosphoribosypyrophosphate synthetase-associated protein, plays a crucial role in cellular metabolism. It is involved in the synthesis of 5-phosphoribose 1-diphosphate, a key precursor in the biosynthesis of nucleotides and nucleic acids. This protein's regulatory function ensures the balance of nucleotide production, which is essential for DNA and RNA synthesis.

Therapeutic significance:

Understanding the role of Phosphoribosyl pyrophosphate synthase-associated protein 2 could open doors to potential therapeutic strategies. Its involvement in nucleotide biosynthesis pathways makes it a candidate for research in diseases where nucleotide balance is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.